Jeff Liter, MBA, Luminary Therapeutics, Minneapolis, MN, describes the advantages of universal immune receptors and how they can address issues relating to chimeric antigen receptor (CAR) T-cell therapies. Patients receiving CAR T-cell therapies can experience antigen escape and T-cell exhaustion and universal immune receptors can overcome these issues by having the ability to be turned on or off. This property enables the antigen to be changed in the event of antigen escape and rest the T cells if T-cell exhaustion occurs. This interview took place at Advanced Therapies Week 2022.
Jeff Liter is an employee of Luminary Therapeutics.